M&As this week: CSL Limited, Alliance Medical, Bio-Techne

29th June 2018 (Last Updated August 12th, 2019 10:39)

CSL Limited has signed an agreement to purchase the remaining 20% interest in Wuhan Zhong Yuan Rui De Biological Products (Ruide) from Humanwell Healthcare Group for $102m.

CSL Limited has signed an agreement to purchase the remaining 20% interest in Wuhan Zhong Yuan Rui De Biological Products (Ruide) from Humanwell Healthcare Group for $102m.

CSL will own 100% stake in Wuhan Zhong Yuan, following the transaction.

Based in Australia, CSL is a biotechnology company that develops and markets products for the treatment of human medical conditions, while Wuhan Zhong Yuan is a biological products and blood products manufacturer and retailer based in China.

Alliance Medical has signed an agreement to purchase Piramal Imaging for an undisclosed sum.

Piramal Imaging’s acquisition will complement the acquirer company’s PET/CT scanning and radio-pharmacy facility services in Europe.

Piramal Imaging will be rebranded and combined with Alliance Medical’s Life Radiopharma business under the Life Brand, following the transaction.

The combined business will include cyclotrons, radio-pharmacies and imaging services. It will also deliver clinical contract radio-pharmaceutical research activities through its German operations in Berlin.

"Alliance Medical has signed an agreement to purchase Piramal Imaging for an undisclosed sum."

Based in the UK, Alliance Medical Group is an imaging and diagnostic services provider, while Piramal Imaging is a Germany-based provider of molecular imaging probes used in oncology.

The acquisition will enable Alliance Medical to boost its molecular imaging capabilities.

Bio-Techne has entered an agreement to purchase Exosome Diagnostics for $575m.

Bio-Techne will pay $250m in cash and up to $325m in milestone payments, as per the agreement.

The acquisition will complement Bio-Techne’s molecular pathology business, Advanced Cellular Diagnostics (ACD). It will enable the company to expand its CAR-T cell marketplace and develop its cell culture-focused product lines.

The transaction will also enable both companies to develop innovative tools to provide better care for patients.

Based in the US, Bio-Techne is a biotechnology and clinical diagnostic company, while Exosome Diagnostics, also based in the US, is a developer of blood-based cancer molecular diagnostics.